What is Medidata Rave and why is it important in clinical trials?

Medidata Rave is an Electronic Data Capture (EDC) system used in clinical trials to collect, manage, and validate clinical trial data from investigational sites. It is the most widely used EDC platform globally — capturing patient data during drug trials that forms the basis of FDA submissions for drug approval. This mission-critical role in drug approval processes creates extraordinary switching costs.

What is Veeva Vault and how does it compete with Medidata?

Veeva Vault is a cloud content management platform Veeva built specifically for life sciences, with modules for clinical trial management (Vault Clinical), regulatory submissions (Vault Regulatory), quality management (Vault QualityOne), and more. Veeva's CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) modules compete directly with Medidata and other clinical software vendors.

Why did Dassault Systèmes acquire Medidata?

Dassault Systèmes (known for CAD/PLM software in aerospace and manufacturing) acquired Medidata for approximately $5.8 billion in 2019 to expand into life sciences — adding clinical trials data and intelligence to its 3DEXPERIENCE platform for product lifecycle management. The combination aimed to apply virtual engineering and simulation concepts to drug development processes.

Data as of: September 18, 2026

brimindinvest.com / compare / veeva-vs-medidataLIVE

VEEV

Veeva Systems Inc. · Technology - Life Sciences Cloud

$263.75

+8.65% this month

VERSUS

COMPARE

MED

Medidata Solutions (Dassault Systèmes) · Technology - Clinical Trials Cloud

$11.96

+5.93% this month

Comparison scoreboard

VEEV LEADS 5/5

AI Scorei

VEEV ✓59.0

MED 24.1

1Y Returni

VEEV ✓-3.94%

MED -15.36%

Fwd P/Ei

VEEV ✓27.41

MED -42.71

Target Up.i

VEEV ✓+4.76%

MED +0.33%

Op. Margini

VEEV ✓29.64%

MED -5.66%

Metrics last refreshed: 9/18/2026

Quick take

VEEV vs MED Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

VEEV (Veeva Systems) is the publicly traded dominant cloud software provider for life sciences with commercial, clinical, regulatory, and data capabilities, while Medidata Solutions was taken private through its 2019 acquisition by Dassault Systèmes and no longer trades independently. Veeva is the primary publicly traded life sciences pure-play cloud software company.

VEEV vs MED covers life sciences cloud software with Veeva as the publicly traded market leader and Medidata as the clinical trials technology leader now operating under Dassault Systèmes' ownership.

Live analysis · updated 9/18/2026

VEEV holds the edge across 5 of 5 key metrics in this comparison. VEEV leads on both 1-year return (-3.94%) and forward P/E quality (27.41x vs -42.71x for MED), a relatively favorable combination of momentum and valuation. VEEV leads on both revenue growth (17.60%) and operating margin (29.64%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for VEEV (+4.76%) than for MED (+0.33%).

Normalized 1Y performance

VEEV

MED

Recent returns

VEEV

MED

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

VEEV

Price target range

analyst mean$294.07
current price$263.75

+4.8% upside to analyst mean

MED · 1 analysts

Price target range

analyst low$12.00
analyst high$12.00
analyst mean$12.00
current price$11.96

+0.3% upside to analyst mean

Who should consider this stock?

VEEV may suit investors who:

Want the dominant life sciences cloud software company with near-monopoly CRM positioning and growing Vault platform adoption across drug development workflows
Value Veeva's high switching costs and customer retention in pharmaceutical company software contracts spanning years or decades
See Vault expansion (regulatory, quality, safety, clinical) as a multi-year revenue growth driver as pharma replaces legacy systems

Medidata is no longer independently traded:

Medidata Solutions was acquired by Dassault Systèmes in 2019 and is no longer a publicly traded U.S. company
For clinical trials software exposure, consider Veeva (VEEV) which has an expanding clinical platform competing with Medidata
Dassault Systèmes (DSY) trades on Euronext Paris for investors wanting European exposure that includes Medidata's clinical trials platform

Performance & AI score

Performance & AI score
Metric	VEEV	MED
AI scorei	59.0	24.1
AI ranki	#190	#3436
Latest closei	$263.75	$11.96
1M returni	+8.65%	+5.93%
6M returni	+42.11%	+18.77%
1Y returni	-3.94%	-15.36%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	VEEV	MED
1Y ago	$9.45K (-5.5%) started 2025-09-18	$8.46K (-15.4%) started 2025-09-17
5Y ago	$8.87K (-11.3%) started 2021-09-20	$689.99 (-93.1%) started 2021-09-17
10Y ago	$65.72K (+557.2%) started 2016-09-19	$5.45K (-45.5%) started 2016-09-19

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	VEEV	MED
Market capi	$45.45B	$133.72M
Trailing P/Ei	46.10	N/A
Forward P/Ei	27.41	-42.71
Price/Salesi	N/A	0.42
EV/Revenuei	11.02	-0.06
Analyst targeti	$294.07	$12.00
Target upsidei	+4.76%	+0.33%

Growth, profitability & risk

Growth, profitability & risk
Metric	VEEV	MED
Revenue growthi	17.60%	-27.60%
Earnings growthi	39.50%	N/A
EPS growthi	+39.50%	N/A
FCF margini	+36.37%	+3.59%
Operating margini	29.64%	-5.66%
Profit margini	29.34%	-8.08%
ROIC proxyi	14.42%	-12.42%
Return on equityi	14.42%	-12.42%
Dividend yieldi	N/A	0.00%
Payout ratioi	0.00%	0.00%
Dividend growth streaki	N/A	No increase yet
Betai	0.92	0.73
Debt/equityi	2.04	14.06
Current ratioi	5.46	4.86
Quick ratioi	5.36	4.09

Correlation

Over the past year, VEEV and MED have moved weakly in the same direction (correlation of 0.16), based on daily returns.

1Y

0.16

-1.0+1.0

5Y

0.24

-1.0+1.0

10Y

0.23

-1.0+1.0

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

VEEV max drawdowni50.55%

MED max drawdowni35.14%

VEEV max wkly dropi16.81%

MED max wkly dropi11.76%

5Y risk snapshot

VEEV max drawdowni53.54%

MED max drawdowni95.42%

VEEV max wkly dropi21.64%

MED max wkly dropi29.09%

10Y risk snapshot

VEEV max drawdowni55.69%

MED max drawdowni96.79%

VEEV max wkly dropi21.64%

MED max wkly dropi31.95%

Performance metrics by period

Performance metrics by period
Period	Metric	VEEV	MED
1Y	Growthi	-5.49%	-15.36%
	CAGRi	-5.50%	-15.37%
	Volatilityi	42.59%	53.29%
	Sharpe ratioi	-0.03	-0.16
	Sortino ratioi	-0.04	-0.32
	Max drawdowni	50.55%	35.14%
	Current drawdowni	13.87%	17.91%
	Avg drawdowni	28.97%	20.96%
	Ulcer Indexi	32.94%	22.30%
	Max daily dropi	9.77%	7.22%
	Max wkly dropi	16.81%	11.76%
5Y	Growthi	-11.30%	-93.88%
	CAGRi	-2.37%	-42.81%
	Volatilityi	39.45%	47.75%
	Sharpe ratioi	0.02	-1.03
	Sortino ratioi	0.03	-1.43
	Max drawdowni	53.54%	95.42%
	Current drawdowni	18.91%	94.21%
	Avg drawdowni	34.31%	67.51%
	Ulcer Indexi	36.54%	73.65%
	Max daily dropi	16.24%	22.47%
	Max wkly dropi	21.64%	29.09%
10Y	Growthi	+557.24%	-59.02%
	CAGRi	+20.73%	-8.54%
	Volatilityi	38.81%	49.20%
	Sharpe ratioi	0.56	-0.03
	Sortino ratioi	0.84	-0.04
	Max drawdowni	55.69%	96.79%
	Current drawdowni	22.65%	95.94%
	Avg drawdowni	22.68%	51.10%
	Ulcer Indexi	28.66%	61.52%
	Max daily dropi	16.24%	28.65%
	Max wkly dropi	21.64%	31.95%

AI Prediction Signali

Members only

Next 5 trading days

VEEV

+2.8%BUY

MED

+1.1%HOLD

Next 30 trading days

VEEV

+6.4%BUY

MED

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	VEEV	MED
Company	Veeva Systems Inc.	Medidata Solutions (Dassault Systèmes)
Sector	Healthcare	Technology - Clinical Trials Cloud
Industry	Health Information Services	Personal Services
Core business	Veeva Systems provides cloud-based software for the global life sciences industry — including CRM (Veeva CRM for pharma sales reps), regulatory (Vault platform), clinical (Veeva Clinical), and data solutions (Veeva Data Cloud) for pharmaceutical and biotech companies.	Medidata Solutions provides cloud-based clinical trials management software — including EDC (electronic data capture), RTSM (randomization and trial supply management), and patient-facing eClinical tools — acquired by Dassault Systèmes in 2019 and now operated as a division.
Investor focus	Investors track Veeva's commercial cloud ARR, Vault platform ARR (replacing legacy systems in clinical, quality, and regulatory), and the long-term growth trajectory as Veeva expands from CRM into the full drug development lifecycle.	Medidata is no longer a publicly traded independent company — it was acquired by Dassault Systèmes in 2019 and operates as Medidata, a Dassault Systèmes company. Investors seeking clinical trials software exposure can access it through Dassault Systèmes (DSY on Euronext Paris) or through Veeva's expanding clinical portfolio.

VEEV strengths

Veeva CRM is the dominant CRM used by pharmaceutical sales representatives globally — near-monopoly positioning creates extraordinary switching costs
Vault platform is systematically replacing legacy document management systems across clinical, quality, regulatory, and safety departments
Life sciences focus provides deep domain expertise that horizontal CRM or cloud platforms lack — critical for pharma's complex regulatory environment

MED strengths

Medidata Rave is the most widely used electronic data capture (EDC) platform in clinical trials globally — used in trials for 95%+ of top 25 pharmaceutical companies
Unified clinical data platform spanning EDC, RTSM, eTMF, and patient data provides a comprehensive clinical operations solution
Dassault Systèmes' 3DEXPERIENCE platform integration expands Medidata's scientific design and virtual trial capabilities

Risks to watch — VEEV

Veeva transitioned from Salesforce platform to its own Veeva Vault CRM — this migration creates risk for some legacy Veeva-on-Salesforce customers
Competition from IQVIA technology solutions and increasingly from niche clinical and regulatory software vendors for specific Vault modules
Life sciences industry consolidation (M&A between pharma companies) can reduce the total count of independent software-buying entities

Risks to watch — MED

Medidata is no longer independently publicly traded — it is a division of French conglomerate Dassault Systèmes
Veeva has expanded its clinical platform to compete directly with Medidata for clinical data management contracts
Investors seeking clinical trials software exposure through public U.S. markets should consider Veeva (VEEV) for life sciences cloud exposure

Frequently asked questions

Veeva CRM (now Veeva Vault CRM) is a pharmaceutical-specific customer relationship management tool for pharma sales representatives and medical science liaisons to track interactions with physicians, manage samples, and document medical education activity — subject to FDA regulations requiring detailed records of pharmaceutical promotions. Veeva's deep regulatory compliance features and pharma-specific workflows make it the standard tool at virtually every major pharmaceutical company.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons